Acquisition and Market Presence Following its acquisition by Catalent Pharma Solutions in 2017 for $950 million, Cook Pharmica has been integrated into a larger biopharmaceutical services platform, indicating opportunities for collaboration with companies seeking comprehensive biologics development and manufacturing support.

Specialized Biologics Focus As a biologics-focused contract development and manufacturing organization, Cook Pharmica presents a compelling partner for clients in need of biologic drug development, especially those targeting innovative therapeutics or complex molecule production.

Growth Potential With an estimated revenue between $50 million and $100 million and a sizable workforce of up to 1,000 employees, Cook Pharmica offers significant capacity for scaling manufacturing needs and expanding service offerings within the biologics sector.

Industry Position & Competition Positioned among industry leaders like Samsung Biologics and WuXi AppTec, Cook Pharmica’s niche as a biologics specialist represents opportunities to differentiate in the competitive biologics CDMO market, especially by leveraging its recent corporate backing.

Digital Engagement & Data Insights Utilizing modern analytics and tracking tools such as Google Analytics and Facebook Pixel, Cook Pharmica demonstrates digital engagement efforts that can be tapped into for targeted outreach and to better understand market trends and customer needs.